104 related articles for article (PubMed ID: 12432165)
1. Acute effects of Advance: a potential reduced exposure product for smokers.
Breland AB; Evans SE; Buchhalter AR; Eissenberg T
Tob Control; 2002 Dec; 11(4):376-8. PubMed ID: 12432165
[TBL] [Abstract][Full Text] [Related]
2. Tobacco specific nitrosamines and potential reduced exposure products for smokers: a preliminary evaluation of Advance.
Breland AB; Acosta MC; Eissenberg T
Tob Control; 2003 Sep; 12(3):317-21. PubMed ID: 12958395
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers.
Cobb CO; Weaver MF; Eissenberg T
Tob Control; 2010 Oct; 19(5):367-73. PubMed ID: 19346218
[TBL] [Abstract][Full Text] [Related]
4. Clinical laboratory evaluation of potential reduced exposure products for smokers.
Breland AB; Kleykamp BA; Eissenberg T
Nicotine Tob Res; 2006 Dec; 8(6):727-38. PubMed ID: 17132520
[TBL] [Abstract][Full Text] [Related]
5. A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects.
Vansickel AR; Cobb CO; Weaver MF; Eissenberg TE
Cancer Epidemiol Biomarkers Prev; 2010 Aug; 19(8):1945-53. PubMed ID: 20647410
[TBL] [Abstract][Full Text] [Related]
6. Evaluating acute effects of potential reduced-exposure products for smokers: clinical laboratory methodology.
Breland AB; Buchhalter AR; Evans SE; Eissenberg T
Nicotine Tob Res; 2002; 4 Suppl 2():S131-40. PubMed ID: 12573174
[TBL] [Abstract][Full Text] [Related]
7. Withdrawal-suppressing effects of a novel smoking system: comparison with own brand, not own brand, and de-nicotinized cigarettes.
Buchhalter AR; Schrinel L; Eissenberg T
Nicotine Tob Res; 2001 May; 3(2):111-8. PubMed ID: 11403724
[TBL] [Abstract][Full Text] [Related]
8. Expanding clinical laboratory tobacco product evaluation methods to loose-leaf tobacco vaporizers.
Lopez AA; Hiler M; Maloney S; Eissenberg T; Breland AB
Drug Alcohol Depend; 2016 Dec; 169():33-40. PubMed ID: 27768968
[TBL] [Abstract][Full Text] [Related]
9. Acute effects of cigarillo smoking.
Blank MD; Nasim A; Hart A; Eissenberg T
Nicotine Tob Res; 2011 Sep; 13(9):874-9. PubMed ID: 21504888
[TBL] [Abstract][Full Text] [Related]
10. Quantitative comparisons between a nicotine delivery device (Eclipse) and conventional cigarette smoking.
Lee EM; Malson JL; Moolchan ET; Pickworth WB
Nicotine Tob Res; 2004 Feb; 6(1):95-102. PubMed ID: 14982693
[TBL] [Abstract][Full Text] [Related]
11. Evaluating oral noncombustible potential-reduced exposure products for smokers.
Blank MD; Eissenberg T
Nicotine Tob Res; 2010 Apr; 12(4):336-43. PubMed ID: 20159791
[TBL] [Abstract][Full Text] [Related]
12. New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure.
Strasser AA; Lerman C; Sanborn PM; Pickworth WB; Feldman EA
Drug Alcohol Depend; 2007 Jan; 86(2-3):294-300. PubMed ID: 16930853
[TBL] [Abstract][Full Text] [Related]
13. Interventions to reduce harm from continued tobacco use.
Stead LF; Lancaster T
Cochrane Database Syst Rev; 2007 Jul; (3):CD005231. PubMed ID: 17636791
[TBL] [Abstract][Full Text] [Related]
14. Nicotine delivery, tolerability and reduction of smoking urge in smokers following short-term use of one brand of electronic cigarettes.
D'Ruiz CD; Graff DW; Yan XS
BMC Public Health; 2015 Sep; 15():991. PubMed ID: 26424091
[TBL] [Abstract][Full Text] [Related]
15. Acute Effects of "Hyping" a Black&Mild Cigarillo.
Blank MD; Cobb CO; Eissenberg T; Nasim A
Nicotine Tob Res; 2016 Apr; 18(4):460-9. PubMed ID: 25782456
[TBL] [Abstract][Full Text] [Related]
16. Escalating doses of transdermal nicotine in heavy smokers: effects on smoking behavior and craving.
Selby P; Andriash K; Zawertailo L; Persad D; Zack M; Busto UE
J Clin Psychopharmacol; 2013 Oct; 33(5):667-74. PubMed ID: 23963055
[TBL] [Abstract][Full Text] [Related]
17. Nicotine and carbon monoxide exposure from inhalation of cigarillo smoke.
Koszowski B; Rosenberry ZR; Kanu A; Viray LC; Potts JL; Pickworth WB
Pharmacol Biochem Behav; 2015 Dec; 139(Pt A):7-14. PubMed ID: 26459155
[TBL] [Abstract][Full Text] [Related]
18. A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders: trial design and protocol.
Allen SI; Foulds J; Pachas GN; Veldheer S; Cather C; Azzouz N; Hrabovsky S; Hameed A; Yingst J; Hammett E; Modesto J; Krebs NM; Zhu J; Liao J; Muscat JE; Richie J; Evins AE
BMC Public Health; 2017 Jan; 17(1):100. PubMed ID: 28103841
[TBL] [Abstract][Full Text] [Related]
19. A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part B: Safety and subjective effects.
Walele T; Sharma G; Savioz R; Martin C; Williams J
Regul Toxicol Pharmacol; 2016 Feb; 74():193-9. PubMed ID: 26702788
[TBL] [Abstract][Full Text] [Related]
20. Effect of reducing the nicotine content of cigarettes on cigarette smoking behavior and tobacco smoke toxicant exposure: 2-year follow up.
Benowitz NL; Nardone N; Dains KM; Hall SM; Stewart S; Dempsey D; Jacob P
Addiction; 2015 Oct; 110(10):1667-75. PubMed ID: 26198394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
